Short answer
CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on August 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.
CorMedix Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, cash position and operating updates
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $101.9M, up from $39.7M, reflecting DefenCath sales $66.1M and Melinta portfolio contribution $35.8M
- Net income $26.0M, diluted EPS $0.29, adjusted EBITDA $58.7M versus $22.4M year over year
- FY 2026 revenue guidance maintained at $325M-$345M, while adjusted EBITDA guidance increased to $125M-$140M
- New multi-year DefenCath agreement adds all top five U.S. dialysis providers, with pilot ordering beginning in Q3
- Cash and short-term investments $256.7M, supporting commercial expansion and pipeline development without near-term funding pressure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CorMedix Inc. 8-K filings
Get the next CRMD 8-K as it lands
Follow CRMD for push alerts, or ask the research agent what this filing means.